AorticLab

Executive Summary

AorticLab is an Italian, pre-clinical medical device company dedicated to revolutionizing the treatment of aortic valve stenosis. Founded in 2015 and headquartered in Milan, the company aims to develop safer and more effective therapies for this life-threatening condition, which affects millions globally. While specific product details remain undisclosed, AorticLab's mission emphasizes innovation and trust, suggesting a novel approach to transcatheter or surgical valve replacement. The company is currently in the pre-clinical stage, focusing on design optimization and animal studies to validate its technology. AorticLab operates in the competitive cardiovascular device market, but its focus on improved safety and superior outcomes could differentiate it from established players. The company's progress will depend on successful pre-clinical data, regulatory strategy, and funding to advance toward first-in-human trials.

Upcoming Catalysts (preview)

• Q3 2026Initiation of First-in-Human (FIH) Trial40% success
• Q4 2026Securing Series A or B Financing60% success
• Q1 2027Receipt of FDA Breakthrough Device Designation30% success